Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation |
Glatt Sophie1, Baeten Dominique L.P.23, Baker Terry S.1, Griffiths Meryn R.1, Ionescu Lucian2, Lawson Alastair D.G.1, Maroof Ash1, Oliver Ruth1, Popa Serghei4, Strimenopoulou Foteini1, Vajjah Pavan1, Watling Mark I.L1, 3, Miossec Pierre J.5, Shaw Stevan1 |
4 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
|
Annals of the Rheumatic Diseases |
Nr. / 2018 / ISSN - /ISSNe 0003-4967 |
Disponibil online 8 May, 2018. Descarcări-0. Vizualizări-932 |
----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
1-20 of 26